Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia

Leukemia Research

Volumn 33, Issue 10, 2009, Pages 1335-1343

  Boelens, Jerina ^a   Lust, Sofie ^a   Van Bockstaele, Femke ^a   Van Gele, Mireille ^a   Janssens, Ann ^a   Derycke, Lara ^a   Vanhoecke, Barbara ^a   Philippé, Jan ^a   Bracke, Marc ^a   Offner, Fritz ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Apoptosis; Chronic lymphocytic leukemia; Glucocorticoids; SYK; ZAP 70

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; FLUDARABINE; METHYLPREDNISOLONE; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; PROTEIN TYROSINE PHOSPHATASE 1B; RITUXIMAB; STEROID;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GAMMA RADIATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION RESPONSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; SIGNAL TRANSDUCTION;

ADRENAL CORTEX HORMONES; ANNEXIN A5; APOPTOSIS; CHLORAMBUCIL; DOWN-REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METHYLPREDNISOLONE; PLASMIDS; PROGNOSIS; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; VIDARABINE; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 67649386486     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.02.022     Document Type: Article

References (50)

1. Hamblin T.J., Orchard J.A., Ibbotson R.E., Davies Z., Thomas P.W., Stevenson F.K., et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99 (2002) 1023-1029
2. Hamblin T.J. Prognostic marhers in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20 (2007) 455-468
3. Van Bockstaele F., Verhasselt B., and Philippé J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 23 (2009) 25-47
4. Rosenwald A., Alizadeh A.A., Widhopf G., Simon R., Davis R.E., Yu X., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia. J Exp Med 194 (2001) 1639-1647
5. Klein U., Tu Y., Stolovitzky G.A., Mattioli M., Cattoretti G., Husson H., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194 (2001) 1625-1638
6. Rassenti L.Z., Huynh L., Toy T.L., Chen L., Keating M.J., Gribben J.G., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351 (2004) 893-901
7. Chen L., Widhopf G., Huynh L., Rassenti L., Rai K.R., Weiss, et al. Expression of ZAP-70 is associated with increased B-cell receptor signalling in chronic lymophocytic leukemia. Blood 100 (2002) 4609-4614
8. Chen L., Apgar J., Huynh L., Dicker F., Ciago-McGahan T., Rassenti L., et al. ZAP-70 directly enhances IgM signalling in chronic lymphocytic leukemia. Blood 105 (2005) 2036-2041
9. Gobessi S., Laurenti L., Longo P.G., Sica S., Leone G., and Efremov D.G. ZAP-70 enhances B-cell receptor signalling in spite of absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B-cells. Blood 109 (2007) 2032-2039
10. Van Oers N.S.C., and Weiss A. The Syk/ZAP-70 protein tyrosine kinase connection to antigen receptor signalling processes. Semin Immunol 7 (1995) 227-236
11. Cutrona G., Colombo M., Matis S., Reverbi D., Dono M., Tarantino V., et al. B lymphocytes in humans express ZAP-70 when activated in vivo. Eur J Immunol 36 (2006) 558-569
12. Nolz J.C., Tschumper R.C., Pittner B.T., Darce J.R., Kay N.E., and Jelinek D.F. Chronic lymphocytic leukemia and normal B-cells. ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia 19 (2005) 1018-1024
13. Kipps T.J. The B-cell receptor and ZAP-70 in chronic lymphocytiv leukemia. Best Pract Res Clin Haematol 20 (2007) 415-424
14. Latour S., Chow L.M., and Veillette A. Differential intrinsic enzymatic activity of Syk and ZAP-70 protein-tyrosine kinases. J Biol Chem 271 (1996) 22782-22790
15. Tinhofer I., Steurer M., Leitinger G., Rumpold H., Egle A., Erdel M., et al. The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial. Haematologica 941 (2006) 1291-1293
16. Chandra J., Gilbreath J., Freireich E., Kliche K.-O., Andreeff M., Keating M., et al. Protease activation is required for glucicorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. Blood 90 (1997) 3673-3681
17. Contri A., Brunati A.M., Trentin L., Cabrelle A., Miorin M., Cesaro L., et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 115 (2005) 369-378
18. Bruscoli S., Di Virgilio R., Donato V., Velardi E., Baldoni M., Marchetti C., et al. Genomic and non-genomic effects of different glucocorticoids on mouse thymocyte apoptosis. Eur J Pharmacol 529 (2006) 63-70
19. Greenstein S., Ghias K., Krett N.L., and Rosen S.T. Mechanisms of glucocorticoid-mediated apoptosis in haematological malignancies. Clin Cancer Res 8 (2002) 1681-1694
20. Saklatvala J. Glucocorticoids: do we know how they work?. Arthritis Res 4 (2002) 146-150
21. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348 (2003) 1764-1775
22. Pasquali C., Curchod M.-L., Wälchli S., Espanel X., Guerrier M., Arigoni F., et al. Identification of protein tyrosine phosphatases with specificity for the ligand-activated growth hormone receptor. Mol Endocrinol 17 (2003) 2228-2239
23. Vandesompele J., De Paepe A., and Speleman F. Elimination of primer-dimer artifacts and genomic coaplification using a two-step SYBR green I real-time RT-PCR. Anal Biochem 303 (2002) 95-98
24. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3 (2003) RESEARCH0034.1-34.11
25. Sternfeld L., Krause E., Schmid A., Anderie I., Latas A., Al-Shaldi H., et al. Tyrosine phosphatase PTP1B interacts with TRPV6 in vivo and plays a role in TRPV6-mediated calcium influx in HEK293 cells. Cell Signal 17 (2005) 951-960
26. Anderie I., Schulz I., and Schmid A. Direct interaction between ER membrane-bound PTP1B and its plasma membrane-anchored targets. Cell Signal 19 (2007) 582-592
27. Van Bockstaele F., Pede V., Naessens E., Van Coppernolle S., Van Tendeloo V., Verhasselt B., et al. Efficient gene transfer in CLL by mRNA electroporation. Leukemia 22 (2008) 323-329
28. Castro J.E., Prada C.E., Loria O., Kamal A., Chen L., Burrows F., et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signalling in chronic lymphocytic leukemia. Blood 106 (2005) 2506-2512
29. Martin S., Kronenwett R., Vandenbulcke K., Offner F., Kliszewski S., Janssens A., et al. B-CLL lymphocytes with mutated and unmutated rearranged immunoglobulin genes respond to methylprednisolone by significantly different molecular pathways as revealed by gene expression profiling. Abstracts of the X International Workshop on CLL, 10-12 October 2003. Stresa, Lake Maggiore, Italy. Leuk Lymphoma 44 Suppl. 2 (2003) S1-S56
30. Bandyopadhyay D., Kusari A., Kenner K.A., Liu F., Chernoff J., Gustafson T.A., et al. Protein-tyrosine phosphatase 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin. J Biol Chem 272 (1997) 1639-1645
31. Janssens A., Offner F., Thierens H., and Philippé J. Chapter VII: the "in vitro apoptosis" profile in CLL correlates with some prognostic markers, treatment history and in vivo response to treatment. In: Nabhan C. (Ed). Chronic lymphocytic leukemia research focus. 1st edition (2007), Nova Science Publishers, Hauppauge NY 143-163
32. Kivekäs I., Tobin G., Thunberg U., Vilpo L., Sundström C., Rosenquist R., et al. Ex vivo drug and irradiation sensitivities in hypermutated and unmutated forms of chronic lymphocytic leukemia cells. Leuk Res 27 (2003) 337-341
33. Chen Z., Aston E., and Yu M. Loss of ZAP-70 and low molecular weight phosphotyrosine phosphatase occurs after therapy in a patient with B-chronic lymphocytic leukemia. Leukemia 19 (2005) 1503-1505
34. Poulain S., Benard C., Daudignon A., Le Baron F., Morel P., and Duthilleul P. Is ZAP-70 expression stable over time in B chronic lymphocytic leukemia?. Leuk Lymphoma 48 (2007) 1219-1221
35. Picard D. Heat-shock protein 90, a chaperone for folding and regulation. Cell Mol Life Sci 59 (2002) 1640-1648
36. Ismaili N., and Garabedian M.J. Modulation of glucocorticoid receptor function via phosphorylation. Ann NY Acad Sci 1024 (2004) 86-101
37. Wang Z., Chen W., Kono E., Dang T., and Garabedian M.J. Modulation of glucocorticoid receptor phosphorylation and transcriptional activity by a C-terminal-associated protein phosphatase. Mol Endocrinol 21 (2007) 625-634
38. Bartis D., Boldizsar F., Szabo M., Palinkas L., Nemeth P., and Berki T. Dexamethasone induces rapid tyrosine-phosphorylation of ZAP-70 in Jurkat cells. J Steroid Biochem Mol Biol 98 (2006) 147-154
39. Bartis D., Boldizsár F., Kvell K., Szabó M., Pálinkás L., Németh P., et al. Intemolecular relations between the glucocorticoid receptor, ZAP-70 kinase, and Hsp-90. Biochem Biophys Res Commun 354 (2007) 253-258
40. Geeraerts B, Rassenti LZ, Elewaut D, Offner F, Kipps TJ, Deforce D. Differential vimentin processing in chronic lymphocytic leukemia identified by differential proteome analysis. United States Provisional Patent Application filed on 16 February, 2007, Serial No. 11/675,958 PROGNOSTIC MARKERS IN CHRONIC LYMPHOCYTIC LEUKEMIA.
41. Almon R.R., DuBois D.C., Jin J.Y., and Jusko W.J. Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle. J Endocrinol 184 (2005) 219-232
42. Thomopoulos P., and Marie J.P. Insulin receptors in acute and chronic lymphoid leukemias. Eur J Clin Invest 10 (1980) 387-392
43. Chen P.-M., Kwan S.-H., Hwang T.-S., Chiang B.N., and Chou C.-K. Insulin receptors on leukemia and lymphoma cells. Blood 62 (1983) 251-255
44. Haj F.G., Verveer P.J., Squire A., Neel B.G., and Bastiaens P.I.H. Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science 295 (2002) 1708-1711
45. Tonks N.K. PTP1B: from the sidelines to the frontlines!. FEBS Lett 546 (2003) 140-148
46. Mustelin T., and Taskén K. Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem J 371 (2003) 15-27
47. Watts J.D., Affolter M., Krebs D.L., Wange R.L., Samelson L.E., and Aebersold R. Identification by electrospray ionization mass spectrometry of the sites of tyrosine phosphorylation induced in activated Jurkat T cells on the protein tyrosine kinase ZAP-70. J Biol Chem 269 (1994) 29520-29529
48. Thornton P.D., Matutes E., Bosanquet A.G., Lakhani A.K., Grech H., Ropner J.E., et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 82 (2003) 759-765
49. Wiesmann C., Barr K.J., Kung J., Zhu J., Erlanson D.A., Shen W., et al. Allosteric inhibition of protein tyrosine phosphatase 1B. Nat Struct Mol Biol 11 (2004) 730-737
50. Zhang S., and Zhang Z.Y. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discov Today 12 (2007) 373-381